Optimizing Patient Care in EGFR-Mutated NSCLC: AE Management and Supportive Care Strategies : Episode 1
Optimizing EGFR-Targeted Therapy in NSCLC: Practical Management Strategies for Nurses and Physicians
Panelists discuss how adverse event profiles, management strategies, and patient education approaches differ among EGFR-targeted therapies for non–small cell lung cancer, including oral tyrosine kinase inhibitors like osimertinib and infusion therapies like amivantamab, with emphasis on monitoring requirements and treatment sequencing decisions.
Video content above is prompted by the following:
- How does the adverse event (AE) profile differ among key therapies for EGFR-mutated non–small cell lung cancer, such as osimertinib, amivantamab, and other treatment options?
- What are the most common and concerning AEs for each therapy?
- How do these distinct AE profiles influence treatment selection and sequencing decisions?
- How does your AE management and patient education approach vary when managing AEs from different EGFR-targeted therapies?
- What are the key differences in monitoring and management strategies for oral tyrosine kinase inhibitors like osimertinib vs infusion therapies like amivantamab?
- How do you adapt your patient education to address the unique challenges of each therapy’s AE profile?
Related Content
